Wedbush raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $19.00 (from $18.00) while maintaining an Outperform rating.

Analyst David Nierengarten commented, "KPTI has a lot riding on STORM, with success opening the doors to near-term commercialization of selinexor for MM; we continue to recommend shares ahead of the data, with interim results and established efficacy/safety profile indicating sel should meet the achievable standard for accelerated approval in the last-line setting being studied. We are ticking up our PT to $19 on the passage of time, and highlight the $5+ in upside to our new target that positive STORM data would create."